Refractory Graft-Versus-Host Disease–Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success

Koji Kawamura, Hideki Nakasone, Saiko Kurosawa, Kazuki Yoshimura, Yukiko Misaki, Ayumi Gomyo, Jin Hayakawa, Masaharu Tamaki, Yu Akahoshi, Machiko Kusuda, Kazuaki Kameda, Hidenori Wada, Yuko Ishihara, Miki Sato, Kiriko Terasako-Saito, Misato Kikuchi, Shun ichi Kimura, Aki Tanihara, Shinichi Kako, Heiwa KanamoriTakehiko Mori, Satoshi Takahashi, Shuichi Taniguchi, Yoshiko Atsuta, Yoshinobu Kanda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The aim of this study was to develop a new composite endpoint that accurately reflects the long-term success of allogeneic hematopoietic stem cell transplantation (allo-HSCT), as the conventional graft-versus-host disease (GVHD)–free, relapse-free survival (GRFS) overestimates the impact of GVHD. First, we validated current GRFS (cGRFS), which recently was proposed as a more accurate endpoint of long-term transplant success. cGRFS was defined as survival without disease relapse/progression or active chronic GVHD at a given time after allo-HSCT, calculated using 2 distinct methods: a linear combination of a Kaplan-Meier estimates approach and a multistate modelling approach. Next, we developed a new composite endpoint, refractory GRFS (rGRFS). rGRFS was calculated similarly to conventional GRFS treating grade III to IV acute GVHD, chronic GVHD requiring systemic treatment, and disease relapse/progression as events, except that GVHD that resolved and did not require systemic treatment at the last evaluation was excluded as an event in rGRFS. The 2 cGRFS curves obtained using 2 different approaches were superimposed and both were superior to that of conventional GRFS, reflecting the proportion of patients with resolved chronic GVHD. Finally, the curves of cGRFS and rGRFS overlapped after the first 2 years of post-transplant follow-up. These results suggest that cGRFS and rGRFS more accurately reflect transplant success than conventional GRFS. Especially, rGRFS can be more easily calculated than cGRFS and analyzed with widely used statistical approaches, whereas cGRFS more accurately represents the burden of GVHD-related morbidity in the first 2 years after transplantation.

Original languageEnglish
JournalBiology of Blood and Marrow Transplantation
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Graft vs Host Disease
Transplants
Recurrence
Survival
Hematopoietic Stem Cell Transplantation
Disease Progression
Kaplan-Meier Estimate
Transplantation
Morbidity
Therapeutics

Keywords

  • Acute GVHD
  • Allogeneic hematopoietic stem cell transplantation
  • Chronic GVHD
  • Endpoint
  • Quality of life

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Refractory Graft-Versus-Host Disease–Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success. / Kawamura, Koji; Nakasone, Hideki; Kurosawa, Saiko; Yoshimura, Kazuki; Misaki, Yukiko; Gomyo, Ayumi; Hayakawa, Jin; Tamaki, Masaharu; Akahoshi, Yu; Kusuda, Machiko; Kameda, Kazuaki; Wada, Hidenori; Ishihara, Yuko; Sato, Miki; Terasako-Saito, Kiriko; Kikuchi, Misato; Kimura, Shun ichi; Tanihara, Aki; Kako, Shinichi; Kanamori, Heiwa; Mori, Takehiko; Takahashi, Satoshi; Taniguchi, Shuichi; Atsuta, Yoshiko; Kanda, Yoshinobu.

In: Biology of Blood and Marrow Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

Kawamura, K, Nakasone, H, Kurosawa, S, Yoshimura, K, Misaki, Y, Gomyo, A, Hayakawa, J, Tamaki, M, Akahoshi, Y, Kusuda, M, Kameda, K, Wada, H, Ishihara, Y, Sato, M, Terasako-Saito, K, Kikuchi, M, Kimura, SI, Tanihara, A, Kako, S, Kanamori, H, Mori, T, Takahashi, S, Taniguchi, S, Atsuta, Y & Kanda, Y 2018, 'Refractory Graft-Versus-Host Disease–Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2018.02.004
Kawamura, Koji ; Nakasone, Hideki ; Kurosawa, Saiko ; Yoshimura, Kazuki ; Misaki, Yukiko ; Gomyo, Ayumi ; Hayakawa, Jin ; Tamaki, Masaharu ; Akahoshi, Yu ; Kusuda, Machiko ; Kameda, Kazuaki ; Wada, Hidenori ; Ishihara, Yuko ; Sato, Miki ; Terasako-Saito, Kiriko ; Kikuchi, Misato ; Kimura, Shun ichi ; Tanihara, Aki ; Kako, Shinichi ; Kanamori, Heiwa ; Mori, Takehiko ; Takahashi, Satoshi ; Taniguchi, Shuichi ; Atsuta, Yoshiko ; Kanda, Yoshinobu. / Refractory Graft-Versus-Host Disease–Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success. In: Biology of Blood and Marrow Transplantation. 2018.
@article{8c2348c8aaad4ff69681ddc23ffbbd14,
title = "Refractory Graft-Versus-Host Disease–Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success",
abstract = "The aim of this study was to develop a new composite endpoint that accurately reflects the long-term success of allogeneic hematopoietic stem cell transplantation (allo-HSCT), as the conventional graft-versus-host disease (GVHD)–free, relapse-free survival (GRFS) overestimates the impact of GVHD. First, we validated current GRFS (cGRFS), which recently was proposed as a more accurate endpoint of long-term transplant success. cGRFS was defined as survival without disease relapse/progression or active chronic GVHD at a given time after allo-HSCT, calculated using 2 distinct methods: a linear combination of a Kaplan-Meier estimates approach and a multistate modelling approach. Next, we developed a new composite endpoint, refractory GRFS (rGRFS). rGRFS was calculated similarly to conventional GRFS treating grade III to IV acute GVHD, chronic GVHD requiring systemic treatment, and disease relapse/progression as events, except that GVHD that resolved and did not require systemic treatment at the last evaluation was excluded as an event in rGRFS. The 2 cGRFS curves obtained using 2 different approaches were superimposed and both were superior to that of conventional GRFS, reflecting the proportion of patients with resolved chronic GVHD. Finally, the curves of cGRFS and rGRFS overlapped after the first 2 years of post-transplant follow-up. These results suggest that cGRFS and rGRFS more accurately reflect transplant success than conventional GRFS. Especially, rGRFS can be more easily calculated than cGRFS and analyzed with widely used statistical approaches, whereas cGRFS more accurately represents the burden of GVHD-related morbidity in the first 2 years after transplantation.",
keywords = "Acute GVHD, Allogeneic hematopoietic stem cell transplantation, Chronic GVHD, Endpoint, Quality of life",
author = "Koji Kawamura and Hideki Nakasone and Saiko Kurosawa and Kazuki Yoshimura and Yukiko Misaki and Ayumi Gomyo and Jin Hayakawa and Masaharu Tamaki and Yu Akahoshi and Machiko Kusuda and Kazuaki Kameda and Hidenori Wada and Yuko Ishihara and Miki Sato and Kiriko Terasako-Saito and Misato Kikuchi and Kimura, {Shun ichi} and Aki Tanihara and Shinichi Kako and Heiwa Kanamori and Takehiko Mori and Satoshi Takahashi and Shuichi Taniguchi and Yoshiko Atsuta and Yoshinobu Kanda",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2018.02.004",
language = "English",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Refractory Graft-Versus-Host Disease–Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success

AU - Kawamura, Koji

AU - Nakasone, Hideki

AU - Kurosawa, Saiko

AU - Yoshimura, Kazuki

AU - Misaki, Yukiko

AU - Gomyo, Ayumi

AU - Hayakawa, Jin

AU - Tamaki, Masaharu

AU - Akahoshi, Yu

AU - Kusuda, Machiko

AU - Kameda, Kazuaki

AU - Wada, Hidenori

AU - Ishihara, Yuko

AU - Sato, Miki

AU - Terasako-Saito, Kiriko

AU - Kikuchi, Misato

AU - Kimura, Shun ichi

AU - Tanihara, Aki

AU - Kako, Shinichi

AU - Kanamori, Heiwa

AU - Mori, Takehiko

AU - Takahashi, Satoshi

AU - Taniguchi, Shuichi

AU - Atsuta, Yoshiko

AU - Kanda, Yoshinobu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The aim of this study was to develop a new composite endpoint that accurately reflects the long-term success of allogeneic hematopoietic stem cell transplantation (allo-HSCT), as the conventional graft-versus-host disease (GVHD)–free, relapse-free survival (GRFS) overestimates the impact of GVHD. First, we validated current GRFS (cGRFS), which recently was proposed as a more accurate endpoint of long-term transplant success. cGRFS was defined as survival without disease relapse/progression or active chronic GVHD at a given time after allo-HSCT, calculated using 2 distinct methods: a linear combination of a Kaplan-Meier estimates approach and a multistate modelling approach. Next, we developed a new composite endpoint, refractory GRFS (rGRFS). rGRFS was calculated similarly to conventional GRFS treating grade III to IV acute GVHD, chronic GVHD requiring systemic treatment, and disease relapse/progression as events, except that GVHD that resolved and did not require systemic treatment at the last evaluation was excluded as an event in rGRFS. The 2 cGRFS curves obtained using 2 different approaches were superimposed and both were superior to that of conventional GRFS, reflecting the proportion of patients with resolved chronic GVHD. Finally, the curves of cGRFS and rGRFS overlapped after the first 2 years of post-transplant follow-up. These results suggest that cGRFS and rGRFS more accurately reflect transplant success than conventional GRFS. Especially, rGRFS can be more easily calculated than cGRFS and analyzed with widely used statistical approaches, whereas cGRFS more accurately represents the burden of GVHD-related morbidity in the first 2 years after transplantation.

AB - The aim of this study was to develop a new composite endpoint that accurately reflects the long-term success of allogeneic hematopoietic stem cell transplantation (allo-HSCT), as the conventional graft-versus-host disease (GVHD)–free, relapse-free survival (GRFS) overestimates the impact of GVHD. First, we validated current GRFS (cGRFS), which recently was proposed as a more accurate endpoint of long-term transplant success. cGRFS was defined as survival without disease relapse/progression or active chronic GVHD at a given time after allo-HSCT, calculated using 2 distinct methods: a linear combination of a Kaplan-Meier estimates approach and a multistate modelling approach. Next, we developed a new composite endpoint, refractory GRFS (rGRFS). rGRFS was calculated similarly to conventional GRFS treating grade III to IV acute GVHD, chronic GVHD requiring systemic treatment, and disease relapse/progression as events, except that GVHD that resolved and did not require systemic treatment at the last evaluation was excluded as an event in rGRFS. The 2 cGRFS curves obtained using 2 different approaches were superimposed and both were superior to that of conventional GRFS, reflecting the proportion of patients with resolved chronic GVHD. Finally, the curves of cGRFS and rGRFS overlapped after the first 2 years of post-transplant follow-up. These results suggest that cGRFS and rGRFS more accurately reflect transplant success than conventional GRFS. Especially, rGRFS can be more easily calculated than cGRFS and analyzed with widely used statistical approaches, whereas cGRFS more accurately represents the burden of GVHD-related morbidity in the first 2 years after transplantation.

KW - Acute GVHD

KW - Allogeneic hematopoietic stem cell transplantation

KW - Chronic GVHD

KW - Endpoint

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85044143804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044143804&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.02.004

DO - 10.1016/j.bbmt.2018.02.004

M3 - Article

C2 - 29476953

AN - SCOPUS:85044143804

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -